More than two years after an initial FDA approval in melanoma, Bristol Myers Squibb is moving its PD-1/LAG-3 combo Opdualag into registrational testing in one of the most important oncology disease ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...
Luci indicated the company is focused on securing additional funding opportunities to support the Phase 3 ibezapolstat clinical trial program and expects further updates on funding initiatives in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results